Germline variants and response to systemic therapy in advanced prostate cancer

Pharmacogenomics. 2020 Jan;21(1):75-81. doi: 10.2217/pgs-2019-0125.

Abstract

Our current understanding of prostate cancer pharmacogenomics is growing at a rapid pace. Apart from evaluating relevant biomarkers and genomic alterations in tumor tissues, an increasing focus is being placed on decoding the impact of germline alterations on prostate cancer and its treatment. Herein we summarize various germline variants that have shown to associate with response to systemic therapy in men with advanced prostate cancer. Covered biomarkers include HSD3B1, SLCO2B1, SULT1E1, TRMT11, CYP17A1, CYP1B1, genes involved in homologous recombination and DNA mismatch repair.

Keywords: CYP17A1; HSD3B1; PARP; SLCO2B1; germline variants; prostate cancer pharmacogenomics.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor / genetics
  • DNA Mismatch Repair / genetics
  • DNA Repair / drug effects
  • Germ Cells / drug effects
  • Germ-Line Mutation / drug effects
  • Homologous Recombination / genetics
  • Humans
  • Male
  • Multienzyme Complexes / genetics*
  • Organic Anion Transporters / genetics*
  • Poly(ADP-ribose) Polymerases / genetics
  • Progesterone Reductase / genetics*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / pathology
  • Steroid 17-alpha-Hydroxylase / genetics*
  • Steroid Isomerases / genetics*

Substances

  • 3 beta-hydroxysteroid oxidoreductase-delta(5) 3-ketosteroid isomerase
  • Biomarkers, Tumor
  • Multienzyme Complexes
  • Organic Anion Transporters
  • SLCO2B1 protein, human
  • Progesterone Reductase
  • CYP17A1 protein, human
  • Steroid 17-alpha-Hydroxylase
  • Poly(ADP-ribose) Polymerases
  • Steroid Isomerases